Study OEV-121A – Phase I, Booster dose memory study

A Booster study was conducted in a subset of the participants from the OEV121 study 18-24 months after the initial two doses. The immune responses in the participants that received the booster dose were comparable, or even higher, against the primary vaccine antigens than what was observed after only the initial two doses. The results also suggest that a single vaccine dose may be sufficient to boost mucosal immune responses several years after priming vaccination. The vaccine was safe and well tolerated.

A.Lundgren, Vaccine 2016. Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine